Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry
Authors:
- María del Carmen VenneraMVMaría del Carmen Vennera
- Francisco J. ÁlvarezFÁFrancisco J. Álvarez
- Juan F MedinaJMJuan F Medina
- Luis BorderíasLBLuis Borderías
- Concha PellicerCPConcha Pellicer
- Héctor GonzálezHGHéctor González
- José A GullónJGJosé A Gullón
- Eva Martínez-MoragónEMEva Martínez-Moragón
- Carlos SabadellCSCarlos Sabadell
- Soledad ZamarroSZSoledad Zamarro
- César PicadoCPCésar Picado
- 28 January 2013
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 50 (3) , 296-301
Abstract
Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using data from a multicenter registry of severe asthma, we evaluated and compared the clinical outcome of 29 omalizumab-treated severe non-atopic asthmatics with 266 omalizumab-treated severe allergic asthmatics. Effectiveness was assessed by considering severe exacerbations, pulmonary function, the Global Evaluation of Treatment Effectiveness (GETE) scale, and Asthma Control Test (ACT). Results. Omalizumab demonstrated significant improvement in the clinical status of non-atopic asthmatics as measured by GETE, which rose from 1.6 ± 1.1 to 2.8 ± 0.9 [corrected] at 4 months (p = .0215) to 2.9 ± 0.9 at 1 year (p = .0093) and to 3.4 ± 0.6 at 2 years (p = .0078), and by the ACT, which increased from 13.3 ± 5.5 [corrected] to 17.5 ± 5.4 at 4 months (p = .0236) to 17.9 ± 4.8 at 1 year (p = .0136) and to 20.6 ± 3.9 at 2 years (p = .0024). Forced expiratory volume in 1 second (FEV1) improved from 61.0 ± 19.4% to 65.1 ± 17.2 at 4 months to 64.1 ± 24.7 at 1 year and to 67.3 ± 23.0% [corrected] at 2 years, but without significant differences between initial and follow-up measurements (p = .52, .91, and .45, respectively) and exacerbations decreased from 3.1 ± 3.5 to 1.9 ± 2.8 at 1 year (p = .1709) to 1.8 ± 4.4 at 2 years (p = .2344). The results were not significantly different from those obtained in atopic asthmatics. Conclusion. Anti-IgE therapy can be effective in non-atopic severe asthma.Keywords
This publication has 17 references indexed in Scilit:
- Beneficial Effects of Treatment With Anti-IgE Antibodies (Omalizumab) in a Patient With Severe Asthma and Negative Skin-Prick Test ResultsChest, 2011
- Italian real-life experience of omalizumabRespiratory Medicine, 2010
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST studyRespiratory Medicine, 2009
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespiratory Medicine, 2009
- Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in FranceRespiratory Medicine, 2008
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Severe asthma: Lessons from the Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Severity assessment in asthma: An evolving conceptJournal of Allergy and Clinical Immunology, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004